## ForPatients
### *by Roche*

Hepatocellular Carcinoma (HCC)

# A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma

| Trial Status | Trial Runs In | Trial Identifier |
|---|---|---|
| **Active, not recruiting** | **2 Countries** | **NCT04712643 ML42612** |

*The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.*

## *Official Title:*

A Phase III, Open-Label, Randomized Study of On-Demand TACE Combined With Atezolizumab Plus Bevacizumab (Atezo/Bev) or On-Demand TACE Alone in Patients With Untreated Heaptocellular Carcionma

## *Trial Summary:*

This study will evaluate the efficacy and safety of atezolizumab plus bevacizumab combined with on-demand TACE compared to on-demand TACE alone in participants with hepatocellular carcinoma who are at high risk of poorer outcome following TACE treatment.

| **Hoffmann-La Roche**<br>Sponsor | **Phase 3**<br>Phase |
|---|---|

**NCT04712643 ML42612**
Trial Identifiers

## *Eligibility Criteria:*

| **Gender**<br>**All** | **Age**<br>**#18 Years** | **Healthy Volunteers**<br>**No** |
|---|---|---|

## *Inclusion Criteria:*

- Confirmed diagnosis of HCC by histology/ cytology or clinical criteria
- Eligible for TACE treatment
- No prior systemic therapy for HCC, especially immunotherapy
- No prior locoregional therapy to the target lesion(s)
- At least one measurable untreated lesion
- ECOG Performance Status of 0-1

- Child-Pugh class A

## *Exclusion Criteria:*

- Evidence of Vp3/4 and hepatic vein tumor thrombus (HVTT)
- Evidence of extrahepatic spread (EHS)
- Being a candidate for curative treatments
- Any condition representing a contraindication to TACE as determined by the investigators
- Active or history of autoimmune disease or immune deficiency
- Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high risk for bleeding
- A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment
- Evidence of bleeding diathesis or significant coagulopathy